Mativ (MATV) Q3 2026 Earnings Call Transcript

Mativ reported Q3 net sales of $499.5 million, down 2.8%, and adjusted EBITDA of $62.3 million, down 7% year over year; management attributed significant pressure to a Wisconsin tornado, which caused an estimated $20 million–$25 million in lost sales, alongside temporary distribution costs and Canadian tariffs. Filtration & Advanced Materials grew organic sales 11.6% and adjusted EBITDA 20%, while Sustainable & Adhesive Solutions sales fell 10.9%; year-to-date adjusted EBITDA rose 8% to $184.8 million. Management expects Q4 adjusted EBITDA to be broadly stable, with a low-single-digit year-over-year moderation, and continues to target leverage of 2.5–3.5 times by mid-2027.

Analysis

The key debate is whether MATV’s improving mix can outrun a still-fragile balance sheet—not whether the Wisconsin disruption is temporary. FAM’s margin expansion is encouraging, but management attributed part of it to favorable pricing that should taper as input costs catch up. Meanwhile, SAS’s sales recovery will not automatically restore earnings: the three-warehouse network remains a cost drag, and the business-interruption claim is not yet confirmed. The 50% tariff touches a small share of consolidated revenue, but may have a disproportionate effect on the exposed tape flows if customers resist pass-throughs or shift sourcing.

The space-film story has strategic value, but a >30% growth rate without a disclosed revenue base or customer concentration does not yet establish material consolidated earnings contribution. Standard production and a customer ramp through 2027 are catalysts to verify, not a basis to capitalize a large growth premium today. Also, 3.8x leverage leaves little room for execution slippage against the mid-2027 target; $7 million of asset-sale proceeds is not a meaningful deleveraging solution by itself.

Near term, Q4 guidance implies volume growth can coexist with weaker year-on-year EBITDA, so headline sales growth may overstate earnings momentum. Over 1–3 months, watch fulfillment costs, tariff mitigation and FAM input-cost pass-through. Over 6–18 months, the thesis depends on space-film scale, normalized SAS logistics, cash conversion and debt paydown. The contrarian risk is that investors treat all headwinds as transient while underweighting pricing fade and leverage. Without valuation and current price data, the call is monitor rather than chase.

Key Decisions for Investors

• Do not add to MATV solely on the space-film growth rate. Reassess after the next report when management provides evidence of sustained commercial volumes and FAM margins after pricing-cost benefits fade; a lower FAM margin alongside continued input-cost catch-up would weaken the growth-quality case.
• Track SAS recovery as an earnings, not just sales, catalyst: require evidence that fulfillment costs are declining and the business-interruption claim is progressing. If sales recover but distribution costs remain elevated into early 2027, treat the disruption as more persistent than guided.
• Keep leverage as the main downside trigger. The deleveraging thesis is weakened if free cash flow deteriorates or net leverage fails to move toward 3.5x by mid-2027; stronger cash conversion and progress toward that threshold would support revisiting exposure.
• Monitor tariff pass-through and customer order behavior at the exposed tape business. A sustained volume decline or inability to protect pricing would challenge management’s characterization of the consolidated impact as limited.